{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T22:26:48Z","timestamp":1790029608714,"version":"4.0.1"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T00:00:00Z","timestamp":1763769600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Japan Drug Development & Medical Affairs, Eli Lilly Japan"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,13]]},"abstract":"Abstract<\/jats:title>\n \n Objectives<\/jats:title>\n To assess the retention rate, changes in disease activity and patient-reported outcomes (PROs), and predictors of treatment discontinuation among baricitinib-treated patients with rheumatoid arthritis (RA) in routine clinical practice in Japan.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n This ongoing, multi-centre, prospective, observational study (starting February 2021) included \u226520-year-old baricitinib-treated patients with RA. Baricitinib\u2019s retention rate and effectiveness were evaluated until 12\u00a0months. The association between patient characteristics and retention was evaluated using Random Forest analysis.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n This interim analysis included 353 patients (mean [standard deviation; SD] age 63.4 [13.6] years; 70.0% female). The 12-month retention rate was 70.2% (95% confidence interval [CI] 65.1, 74.6). The 12-month remission rates were 35.3%, 41.1%, and 79.6% per Clinical Disease Activity Index, Simplified Disease Activity Index, and Disease Activity Score with 28 joints\u2013C-reactive protein. The mean (SD) changes in PROs from baseline scores were: physician global assessment of disease activity (\u221233.8 [27.8]), patient global assessment of disease activity (\u221218.3 [29.4]), Health Assessment Questionnaire-Disability Index (\u22120.33 [0.53]), and pain (\u221219.4 [27.0]). Ten variables influenced the model\u2019s prediction of treatment discontinuation.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n Evidence from this interim analysis suggested the favourable effectiveness and drug survival of baricitinib in real-world Japanese patients with RA.<\/jats:p>\n <\/jats:sec>","DOI":"10.1093\/mr\/roaf113","type":"journal-article","created":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T12:34:08Z","timestamp":1763382848000},"page":"335-344","source":"Crossref","is-referenced-by-count":2,"title":["Retention of baricitinib-treated patients with rheumatoid arthritis in Japan: Interim results from a prospective observational cohort study"],"prefix":"10.1093","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2646-5765","authenticated-orcid":false,"given":"Yuko","family":"Kaneko","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5533-1497","authenticated-orcid":false,"given":"Chaochen","family":"Wang","sequence":"additional","affiliation":[{"name":"Japan Drug Development & Medical Affairs, Eli Lilly Japan K.K ., Kobe ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoto","family":"Tsujimoto","sequence":"additional","affiliation":[{"name":"Japan Drug Development & Medical Affairs, Eli Lilly Japan K.K ., Kobe ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7302-8692","authenticated-orcid":false,"given":"Masaru","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Japan Drug Development & Medical Affairs, Eli Lilly Japan K.K ., Kobe ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Ikeda","sequence":"additional","affiliation":[{"name":"Department of Rheumatology\/ Rheumatic Disease Center, Dokkyo Medical University , Tochigi ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,11,22]]},"reference":[{"key":"2026041500574648700_ref1","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1016\/S0140-6736(23)01525-8","article-title":"Rheumatoid arthritis","volume":"402","author":"Di Matteo","year":"2023","journal-title":"Lancet"},{"key":"2026041500574648700_ref2","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1001\/jama.2018.13103","article-title":"Diagnosis and Management of Rheumatoid Arthritis: A review","volume":"320","author":"Aletaha","year":"2018","journal-title":"JAMA"},{"key":"2026041500574648700_ref3","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2026041500574648700_ref4","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1002\/acr.24596","article-title":"2021 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis","volume":"73","author":"Fraenkel","year":"2021","journal-title":"Arthritis Care Res"},{"key":"2026041500574648700_ref5","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.berh.2011.10.003","article-title":"Quality of life and the outcome of established rheumatoid arthritis","volume":"25","author":"Kingsley","year":"2011","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"2026041500574648700_ref6","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.jbspin.2020.03.006","article-title":"Predictive factors of treatment persistence in rheumatoid arthritis","volume":"87","author":"Lauper","year":"2020","journal-title":"Joint Bone Spine"},{"key":"2026041500574648700_ref7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14397595.2019.1660028","article-title":"A large observational cohort study of rheumatoid arthritis, IORRA: Providing context for today's treatment options","volume":"30","author":"Yamanaka","year":"2020","journal-title":"Mod Rheumatol"},{"key":"2026041500574648700_ref8","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1093\/mr\/roac089","article-title":"Safety and effectiveness of baricitinib for rheumatoid arthritis in Japanese clinical practice: 24-week results of all-case post-marketing surveillance","volume":"33","author":"Takagi","year":"2023","journal-title":"Mod Rheumatol"},{"key":"2026041500574648700_ref9","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1093\/rheumatology\/keae012","article-title":"Efficacy of Baricitinib in patients with moderate-to-severe rheumatoid arthritis up to 6.5 years of treatment: Results of a long-term study","volume":"63","author":"Caporali","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"2026041500574648700_ref10","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1080\/14397595.2017.1392057","article-title":"Efficacy and safety of baricitinib in Japanese patients with rheumatoid arthritis: Subgroup analyses of four multinational phase 3 randomized trials","volume":"28","author":"Tanaka","year":"2018","journal-title":"Mod Rheumatol"},{"key":"2026041500574648700_ref11","doi-asserted-by":"crossref","first-page":"21907","DOI":"10.1038\/s41598-020-78925-8","article-title":"Predictors for clinical effectiveness of baricitinib in rheumatoid arthritis patients in routine clinical practice: Data from a Japanese multicenter registry","volume":"10","author":"Takahashi","year":"2020","journal-title":"Sci Rep"},{"key":"2026041500574648700_ref12","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1056\/NEJMoa1608345","article-title":"Baricitinib versus placebo or adalimumab in rheumatoid arthritis","volume":"376","author":"Taylor","year":"2017","journal-title":"N Engl J Med"},{"key":"2026041500574648700_ref13","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1093\/mr\/roae064","article-title":"Safety of baricitinib in Japanese patients with rheumatoid arthritis in clinical use: 3-year data of all-case post-marketing surveillance study","volume":"35","author":"Okamoto","year":"2025","journal-title":"Mod Rheumatol"},{"key":"2026041500574648700_ref14","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1136\/annrheumdis-2011-200838","article-title":"Drug retention rates and relevant risk factors for drug discontinuation due to adverse events in rheumatoid arthritis patients receiving anticytokine therapy with different target molecules","volume":"71","author":"Sakai","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"2026041500574648700_ref15","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1093\/rheumatology\/kex337","article-title":"Treatment adherence in systemic lupus erythematosus and rheumatoid arthritis: Time to focus on this important issue","volume":"57","author":"Costedoat-Chalumeau","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"2026041500574648700_ref16","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1136\/ard.2010.138461","article-title":"2010 rheumatoid arthritis classification criteria: An American College of Rheumatology\/European league against rheumatism collaborative initiative","volume":"69","author":"Aletaha","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2026041500574648700_ref17","first-page":"S100","article-title":"The simplified disease activity index (SDAI) and the clinical disease activity index (CDAI): A review of their usefulness and validity in rheumatoid arthritis","volume":"23","author":"Aletaha","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"2026041500574648700_ref18","doi-asserted-by":"crossref","first-page":"R796","DOI":"10.1186\/ar1740","article-title":"Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: Validation of a clinical activity score","volume":"7","author":"Aletaha","year":"2005","journal-title":"Arthritis Res Ther"},{"key":"2026041500574648700_ref19","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1136\/ard.2007.084459","article-title":"Validation of the 28-joint disease activity score (DAS28) and European league against rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate","volume":"68","author":"Wells","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"2026041500574648700_ref20","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/art.1780230202","article-title":"Measurement of patient outcome in arthritis","volume":"23","author":"Fries","year":"1980","journal-title":"Arthritis Rheum"},{"key":"2026041500574648700_ref21","first-page":"789","article-title":"The dimensions of health outcomes: The health assessment questionnaire, disability and pain scales","volume":"9","author":"Fries","year":"1982","journal-title":"J Rheumatol"},{"key":"2026041500574648700_ref22","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1002\/acr.20621","article-title":"Measures of rheumatoid arthritis disease activity: Patient (PtGA) and provider (PrGA) global assessment of disease activity, disease activity score (DAS) and disease activity score with 28-joint counts (DAS28), simplified disease activity index (SDAI), clinical disease activity index (CDAI), patient activity score (PAS) and patient activity score-II (PASII), routine assessment of patient index data (RAPID), rheumatoid arthritis disease activity index (RADAI) and rheumatoid arthritis disease activity Index-5 (RADAI-5), chronic arthritis systemic index (CASI), patient-based disease activity score with ESR (PDAS1) and patient-based disease activity score without ESR (PDAS2), and mean overall index for rheumatoid arthritis (MOI-RA)","volume":"63","author":"Anderson","year":"2011","journal-title":"Arthritis Care Res"},{"issue":"1","key":"2026041500574648700_ref23","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1023\/A:1010933404324","article-title":"Random forests","volume":"45","author":"Breiman","year":"2001","journal-title":"Mach Learn"},{"key":"2026041500574648700_ref24","doi-asserted-by":"crossref","first-page":"e707","DOI":"10.1002\/osp4.707","article-title":"EXIST: EXamining rIsk of excesS adiposiTy-machine learning to predict obesity-related complications","volume":"10","author":"Turchin","year":"2024","journal-title":"Obes Sci Pract"},{"key":"2026041500574648700_ref25","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.3899\/jrheum.101009","article-title":"Incidence and risk factors for serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: A report from the registry of Japanese rheumatoid arthritis patients for Longterm safety","volume":"38","author":"Komano","year":"2011","journal-title":"J Rheumatol"},{"key":"2026041500574648700_ref26","doi-asserted-by":"crossref","first-page":"e000546","DOI":"10.1136\/rmdopen-2017-000546","article-title":"Safety and efficacy of baricitinib in elderly patients with rheumatoid arthritis","volume":"3","author":"Fleischmann","year":"2017","journal-title":"RMD Open"},{"key":"2026041500574648700_ref27","first-page":"73","article-title":"The RA-BE-REAL multinational, prospective, observational study in patients with rheumatoid arthritis receiving Baricitinib, targeted synthetic, or biologic disease-modifying therapies: A 6-month interim analysis","volume":"10","author":"Alten","year":"2023","journal-title":"Rheumatol Ther"},{"key":"2026041500574648700_ref28","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1007\/s40744-023-00597-3","article-title":"Comparative effectiveness, time to discontinuation, and patient-reported outcomes with Baricitinib in rheumatoid arthritis: 2-year data from the multinational, prospective observational RA-BE-REAL study in European patients","volume":"10","author":"Alten","year":"2023","journal-title":"Rheumatol Ther"},{"key":"2026041500574648700_ref29","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1007\/s10067-021-05609-7","article-title":"Drug retention of sarilumab, baricitinib, and tofacitinib in patients with rheumatoid arthritis: The ANSWER cohort study","volume":"40","author":"Ebina","year":"2021","journal-title":"Clin Rheumatol"},{"key":"2026041500574648700_ref30","doi-asserted-by":"crossref","first-page":"1176613","DOI":"10.3389\/fmed.2023.1176613","article-title":"Baricitinib retention rate: 'real-life' data from a mono-centric cohort of patients affected by rheumatoid arthritis","volume":"10","author":"Baldi","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"2026041500574648700_ref31","doi-asserted-by":"crossref","first-page":"100178","DOI":"10.1016\/j.crphar.2024.100178","article-title":"Analysis of survival rate and persistence predictors of baricitinib in real-world data from a large cohort of rheumatoid arthritis patients","volume":"6","author":"Parisi","year":"2024","journal-title":"Curr Res Pharmacol Drug Discov"},{"key":"2026041500574648700_ref32","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1002\/acr.21747","article-title":"Minimum clinically important improvement and patient acceptable symptom state in pain and function in rheumatoid arthritis, ankylosing spondylitis, chronic back pain, hand osteoarthritis, and hip and knee osteoarthritis: Results from a prospective multinational study","volume":"64","author":"Tubach","year":"2012","journal-title":"Arthritis Care Res"},{"key":"2026041500574648700_ref33","first-page":"375","article-title":"THU0196\u00a0efficacy and safety up to 24 weeks of baricitinib for Japanese patients with rheumatoid arthritis in real world multicenter clinical data","volume":"78","author":"Torikai","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2026041500574648700_ref34","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1093\/mr\/roaf006","article-title":"2024 update of the Japan college of rheumatology clinical practice guidelines for the Management of Rheumatoid Arthritis: Secondary publication","volume":"35","author":"Harigai","year":"2025","journal-title":"Mod Rheumatol"},{"issue":"1","key":"2026041500574648700_ref35","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1093\/mr\/roac017","article-title":"Drug treatment algorithm and recommendations from the 2020 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis-secondary publication","volume":"33","author":"Kawahito","year":"2023","journal-title":"Mod Rheumatol"},{"key":"2026041500574648700_ref36","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1136\/ard-2022-223358","article-title":"Efficacy, duration of use and safety of glucocorticoids: A systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis","volume":"82","author":"Bergstra","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2026041500574648700_ref37","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1517\/14740338.2016.1140743","article-title":"Long-term side effects of glucocorticoids","volume":"15","author":"Oray","year":"2016","journal-title":"Expert Opin Drug Saf"},{"key":"2026041500574648700_ref38","doi-asserted-by":"crossref","first-page":"1376476","DOI":"10.3389\/fimmu.2024.1376476","article-title":"The steroid-sparing effect of JAK inhibitors across multiple patient populations","volume":"15","author":"Conigliaro","year":"2024","journal-title":"Front Immunol"},{"key":"2026041500574648700_ref39","doi-asserted-by":"crossref","first-page":"868","DOI":"10.55563\/clinexprheumatol\/pudtpo","article-title":"Efficacy and safety of baricitinib in 446 patients with rheumatoid arthritis: A real-life multicentre study","volume":"39","author":"Guidelli","year":"2021","journal-title":"Clin Exp Rheumatol"},{"key":"2026041500574648700_ref40","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s40744-019-00184-5","article-title":"Retrospective analysis of the impact of adalimumab initiation on corticosteroid utilization and medical costs among biologic-naive patients with rheumatoid arthritis","volume":"7","author":"Spivey","year":"2020","journal-title":"Rheumatol Ther"}],"container-title":["Modern Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mr\/advance-article-pdf\/doi\/10.1093\/mr\/roaf113\/65467645\/roaf113.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/36\/3\/335\/65467645\/roaf113.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/36\/3\/335\/65467645\/roaf113.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T04:57:59Z","timestamp":1776229079000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mr\/article\/36\/3\/335\/8340153"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,22]]},"references-count":40,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,11,22]]},"published-print":{"date-parts":[[2026,4,13]]}},"URL":"https:\/\/doi.org\/10.1093\/mr\/roaf113","relation":{},"ISSN":["1439-7595","1439-7609"],"issn-type":[{"value":"1439-7595","type":"print"},{"value":"1439-7609","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5]]},"published":{"date-parts":[[2025,11,22]]}}}